| . | E. coli, N = 335 . | K. pneumoniae, N = 36 . | Enterobacter spp., N = 19 . | Citrobacter spp., N = 14 . | H. alvei, N = 3 . | K. oxytoca, N = 2 . | P. mirabilis, N = 1 . | Total, N = 410 . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | |
| CTX-M-1 groupa | 243 | 72.5 | 26 | 72.2 | 2 | 10.5 | 1 | 7.1 | 1 | 33.3 | 2 | 100 | 1 | 100 | 276 | 67.3 |
| CTX-M-2 groupb | 1 | 0.3 | 1 | 0.2 | ||||||||||||
| CTX-M-8 | 3 | 0.9 | 3 | 0.7 | ||||||||||||
| CTX-M-9 groupc | 63 | 18.8 | 5 | 13.9 | 1 | 5.3 | 69 | 16.8 | ||||||||
| SHV ESBL | 14 | 4.2 | 6 | 16.7 | 1 | 5.3 | 1 | 50 | 22 | 5.4 | ||||||
| TEM ESBL | 4 | 1.2 | 4 | 1.0 | ||||||||||||
| AmpC | 7 | 2.1 | 18 | 94.7 | 11 | 78.6 | 3 | 100 | 39 | 9.5 | ||||||
| VIM-1 | 1 | 2.8 | 1 | 7.1 | 1 | 50 | 3 | 0.7 | ||||||||
| NDM-1 | 1 | 5.3 | 1 | 0.2 | ||||||||||||
| IMP-8 | 1 | 7.1 | 1 | 0.2 | ||||||||||||
| Othersd | 2 | 0.6 | 1 | 7.1 | 3 | 0.7 | ||||||||||
| . | E. coli, N = 335 . | K. pneumoniae, N = 36 . | Enterobacter spp., N = 19 . | Citrobacter spp., N = 14 . | H. alvei, N = 3 . | K. oxytoca, N = 2 . | P. mirabilis, N = 1 . | Total, N = 410 . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | |
| CTX-M-1 groupa | 243 | 72.5 | 26 | 72.2 | 2 | 10.5 | 1 | 7.1 | 1 | 33.3 | 2 | 100 | 1 | 100 | 276 | 67.3 |
| CTX-M-2 groupb | 1 | 0.3 | 1 | 0.2 | ||||||||||||
| CTX-M-8 | 3 | 0.9 | 3 | 0.7 | ||||||||||||
| CTX-M-9 groupc | 63 | 18.8 | 5 | 13.9 | 1 | 5.3 | 69 | 16.8 | ||||||||
| SHV ESBL | 14 | 4.2 | 6 | 16.7 | 1 | 5.3 | 1 | 50 | 22 | 5.4 | ||||||
| TEM ESBL | 4 | 1.2 | 4 | 1.0 | ||||||||||||
| AmpC | 7 | 2.1 | 18 | 94.7 | 11 | 78.6 | 3 | 100 | 39 | 9.5 | ||||||
| VIM-1 | 1 | 2.8 | 1 | 7.1 | 1 | 50 | 3 | 0.7 | ||||||||
| NDM-1 | 1 | 5.3 | 1 | 0.2 | ||||||||||||
| IMP-8 | 1 | 7.1 | 1 | 0.2 | ||||||||||||
| Othersd | 2 | 0.6 | 1 | 7.1 | 3 | 0.7 | ||||||||||
aCTX-M-1 group: CTX-M-1, CTX-M-15, CTX-M-3, etc.
bCTX-M-2 group: CTX-M-2, CTX-M-4, CTX-M-6, etc.
cCTX-M-9 group: CTX-M-9, CTX-M-14, CTX-M-27, etc.
dOthers: non-susceptibility to third-generation cephalosporins by other mechanisms (e.g. hyperproduction of narrow-spectrum β-lactamases).
| . | E. coli, N = 335 . | K. pneumoniae, N = 36 . | Enterobacter spp., N = 19 . | Citrobacter spp., N = 14 . | H. alvei, N = 3 . | K. oxytoca, N = 2 . | P. mirabilis, N = 1 . | Total, N = 410 . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | |
| CTX-M-1 groupa | 243 | 72.5 | 26 | 72.2 | 2 | 10.5 | 1 | 7.1 | 1 | 33.3 | 2 | 100 | 1 | 100 | 276 | 67.3 |
| CTX-M-2 groupb | 1 | 0.3 | 1 | 0.2 | ||||||||||||
| CTX-M-8 | 3 | 0.9 | 3 | 0.7 | ||||||||||||
| CTX-M-9 groupc | 63 | 18.8 | 5 | 13.9 | 1 | 5.3 | 69 | 16.8 | ||||||||
| SHV ESBL | 14 | 4.2 | 6 | 16.7 | 1 | 5.3 | 1 | 50 | 22 | 5.4 | ||||||
| TEM ESBL | 4 | 1.2 | 4 | 1.0 | ||||||||||||
| AmpC | 7 | 2.1 | 18 | 94.7 | 11 | 78.6 | 3 | 100 | 39 | 9.5 | ||||||
| VIM-1 | 1 | 2.8 | 1 | 7.1 | 1 | 50 | 3 | 0.7 | ||||||||
| NDM-1 | 1 | 5.3 | 1 | 0.2 | ||||||||||||
| IMP-8 | 1 | 7.1 | 1 | 0.2 | ||||||||||||
| Othersd | 2 | 0.6 | 1 | 7.1 | 3 | 0.7 | ||||||||||
| . | E. coli, N = 335 . | K. pneumoniae, N = 36 . | Enterobacter spp., N = 19 . | Citrobacter spp., N = 14 . | H. alvei, N = 3 . | K. oxytoca, N = 2 . | P. mirabilis, N = 1 . | Total, N = 410 . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | n . | % . | |
| CTX-M-1 groupa | 243 | 72.5 | 26 | 72.2 | 2 | 10.5 | 1 | 7.1 | 1 | 33.3 | 2 | 100 | 1 | 100 | 276 | 67.3 |
| CTX-M-2 groupb | 1 | 0.3 | 1 | 0.2 | ||||||||||||
| CTX-M-8 | 3 | 0.9 | 3 | 0.7 | ||||||||||||
| CTX-M-9 groupc | 63 | 18.8 | 5 | 13.9 | 1 | 5.3 | 69 | 16.8 | ||||||||
| SHV ESBL | 14 | 4.2 | 6 | 16.7 | 1 | 5.3 | 1 | 50 | 22 | 5.4 | ||||||
| TEM ESBL | 4 | 1.2 | 4 | 1.0 | ||||||||||||
| AmpC | 7 | 2.1 | 18 | 94.7 | 11 | 78.6 | 3 | 100 | 39 | 9.5 | ||||||
| VIM-1 | 1 | 2.8 | 1 | 7.1 | 1 | 50 | 3 | 0.7 | ||||||||
| NDM-1 | 1 | 5.3 | 1 | 0.2 | ||||||||||||
| IMP-8 | 1 | 7.1 | 1 | 0.2 | ||||||||||||
| Othersd | 2 | 0.6 | 1 | 7.1 | 3 | 0.7 | ||||||||||
aCTX-M-1 group: CTX-M-1, CTX-M-15, CTX-M-3, etc.
bCTX-M-2 group: CTX-M-2, CTX-M-4, CTX-M-6, etc.
cCTX-M-9 group: CTX-M-9, CTX-M-14, CTX-M-27, etc.
dOthers: non-susceptibility to third-generation cephalosporins by other mechanisms (e.g. hyperproduction of narrow-spectrum β-lactamases).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
